Senti Biosciences, Inc. (NASDAQ:SNTI – Get Free Report) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 834,000 shares, a decline of 44.4% from the November 15th total of 1,500,000 shares. Based on an average trading volume of 2,570,000 shares, the days-to-cover ratio […]
Triatomic Management LP boosted its stake in shares of Senti Biosciences, Inc. (NASDAQ:SNTI – Free Report) by 42.5% during the 2nd quarter, Holdings Channel reports. The firm owned 300,533 shares of the company’s stock after acquiring an additional 89,650 shares during the quarter. Triatomic Management LP’s holdings in Senti Biosciences were worth $188,000 as of […]
Senti Biosciences, Inc. (NASDAQ:SNTI – Get Free Report) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,500,000 shares, an increase of 260.1% from the October 31st total of 416,500 shares. Approximately 5.7% of the shares of the company are […]
– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio’s proprietary.
Senti Biosciences, Inc. (NASDAQ:SNTI – Free Report) – Equities researchers at Chardan Capital lowered their FY2023 EPS estimates for shares of Senti Biosciences in a report issued on Tuesday, August 15th. Chardan Capital analyst Y. Livshits now expects that the company will earn ($1.05) per share for the year, down from their prior estimate of […]